Section 217 Advanced Cell Therapy and Regenerative Medicine in CBS/PSP

Section 217: Advanced Cell Therapy and Regenerative Medicine in CBS/PSP

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 217 Advanced Cell Therapy and Regenerative Medicine in CBS/PSP</th>
</tr>
<tr>
<td class="label">Trial</td>
<td>Cell Type</td>
</tr>
<tr>
<td class="label">Kyoto University (Japan)</td>
<td>iPSC-derived DA progenitors</td>
</tr>
<tr>
<td class="label">Bemdaneprocel (BlueRock)</td>
<td>hESC-derived DA progenitors[@bluerock2024]</td>
</tr>
<tr>
<td class="label">STEM-PD (Lund/Cambridge)</td>
<td>hESC-derived DA neurons</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Trophic factor secretion</td>
<td>BDNF, GDNF, NGF, VEGF support neuron survival</td>
</tr>
<tr>
<td class="label">Immunomodulation</td>
<td>Suppress pro-inflammatory microglia, reduce IL-1β, TNF-α</td>
</tr>
<tr>
<td class="label">Anti-apoptotic</td>
<td>Secretion of survival factors protecting neurons</td>
</tr>
<tr>
<td class="label">Endogenous repair</td>
<td>Stimulate native neural stem cell proliferation[@chen2024]</td>
</tr>
<tr>
<td class="label">Mitochondrial transfer</td>
<td>Direct mitochondrial donation to damaged neurons[@nino2023]</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Intravenous</td>
<td>Minimally invasive, repeatable</td>
</tr>
<tr>
<td class="label">Intrathecal</td>
<td>Di

Section 217: Advanced Cell Therapy and Regenerative Medicine in CBS/PSP

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 217 Advanced Cell Therapy and Regenerative Medicine in CBS/PSP</th>
</tr>
<tr>
<td class="label">Trial</td>
<td>Cell Type</td>
</tr>
<tr>
<td class="label">Kyoto University (Japan)</td>
<td>iPSC-derived DA progenitors</td>
</tr>
<tr>
<td class="label">Bemdaneprocel (BlueRock)</td>
<td>hESC-derived DA progenitors[@bluerock2024]</td>
</tr>
<tr>
<td class="label">STEM-PD (Lund/Cambridge)</td>
<td>hESC-derived DA neurons</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Trophic factor secretion</td>
<td>BDNF, GDNF, NGF, VEGF support neuron survival</td>
</tr>
<tr>
<td class="label">Immunomodulation</td>
<td>Suppress pro-inflammatory microglia, reduce IL-1β, TNF-α</td>
</tr>
<tr>
<td class="label">Anti-apoptotic</td>
<td>Secretion of survival factors protecting neurons</td>
</tr>
<tr>
<td class="label">Endogenous repair</td>
<td>Stimulate native neural stem cell proliferation[@chen2024]</td>
</tr>
<tr>
<td class="label">Mitochondrial transfer</td>
<td>Direct mitochondrial donation to damaged neurons[@nino2023]</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Intravenous</td>
<td>Minimally invasive, repeatable</td>
</tr>
<tr>
<td class="label">Intrathecal</td>
<td>Direct CSF exposure</td>
</tr>
<tr>
<td class="label">Intra-arterial</td>
<td>Targeted brain delivery</td>
</tr>
<tr>
<td class="label">Intracerebral</td>
<td>Direct parenchymal delivery</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>MSC Therapy</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Trophic support, immunomodulation</td>
</tr>
<tr>
<td class="label">Onset</td>
<td>Weeks to months</td>
</tr>
<tr>
<td class="label">Durability</td>
<td>May require repeat dosing</td>
</tr>
<tr>
<td class="label">Invasive</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Evidence base</td>
<td>More established</td>
</tr>
<tr>
<td class="label">CBS/PSP suitability</td>
<td>Promising (neuroinflammation)</td>
</tr>
<tr>
<td class="label">Cargo</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">siRNA/ASO</td>
<td>Gene silencing (e.g., MAPT)</td>
</tr>
<tr>
<td class="label">Small molecules</td>
<td>Neuroprotection, anti-inflammatory</td>
</tr>
<tr>
<td class="label">Proteins</td>
<td>Trophic factors (GDNF, BDNF)</td>
</tr>
<tr>
<td class="label">miRNA</td>
<td>Epigenetic modulation</td>
</tr>
<tr>
<td class="label">mRNA</td>
<td>Protein replacement</td>
</tr>
<tr>
<td class="label">Method</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Intracerebral</td>
<td>Putamen/substantia nigra</td>
</tr>
<tr>
<td class="label">Intra-arterial</td>
<td>Cerebral circulation</td>
</tr>
<tr>
<td class="label">IV</td>
<td>Systemic, limited CNS</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Vector</td>
</tr>
<tr>
<td class="label">Voyager Therapeutics</td>
<td>AAV2-GDNF</td>
</tr>
<tr>
<td class="label">Roche/ch2</td>
<td>AAV2-GDNF</td>
</tr>
<tr>
<td class="label">NBI-578</td>
<td>AAV-GDNF</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Consideration</td>
</tr>
<tr>
<td class="label">Target selection</td>
<td>GDNF/CDNF for motor, TrkB for cognitive</td>
</tr>
<tr>
<td class="label">Delivery</td>
<td>Stereotactic intracerebral injection</td>
</tr>
<tr>
<td class="label">Immunosuppression</td>
<td>Not typically required for AAV</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>Potential multi-year effect from single dose</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>May combine with cell therapy</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Therapy</td>
</tr>
<tr>
<td class="label">BlueRock Bemdaneprocel</td>
<td>ESC-DA</td>
</tr>
<tr>
<td class="label">STEM-PD</td>
<td>ESC-DA</td>
</tr>
<tr>
<td class="label">Kyoto iPSC</td>
<td>iPSC-DA</td>
</tr>
<tr>
<td class="label">Herantis CDNF</td>
<td>AAV-CDNF</td>
</tr>
<tr>
<td class="label">NCT04998357</td>
<td>Mitochondria</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Impact</td>
</tr>
<tr>
<td class="label">Age <65</td>
<td>Better graft integration</td>
</tr>
<tr>
<td class="label">Disease duration <5 years</td>
<td>Less neurodegeneration</td>
</tr>
<tr>
<td class="label">Preserved cognition</td>
<td>Better functional recovery</td>
</tr>
<tr>
<td class="label">Limited comorbidity</td>
<td>Able to tolerate procedure</td>
</tr>
<tr>
<td class="label">Strong social support</td>
<td>Adherence to follow-up</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Estimated Cost</td>
</tr>
<tr>
<td class="label">MSC therapy (clinical trial)</td>
<td>Typically free</td>
</tr>
<tr>
<td class="label">iPSC autologous</td>
<td>$150,000-300,000</td>
</tr>
<tr>
<td class="label">Private cell banking</td>
<td>$2,000-5,000</td>
</tr>
<tr>
<td class="label">Gene therapy (compassionate)</td>
<td>$500,000-1,500,000</td>
</tr>
<tr>
<td class="label">International trial participation</td>
<td>Variable</td>
</tr>
</table>

Overview

Advanced cell therapy and regenerative medicine represent the most forward-looking therapeutic strategies for [corticobasal syndrome](/diseases/corticobasal-syndrome) (CBS) and [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy) (PSP). These approaches move beyond neuroprotection to attempt actual restoration of lost neuronal function and circuit connectivity.

This section provides comprehensive coverage of:

• Cell replacement therapies: iPSC-derived, ESC-derived, and neural stem cells
• MSC-based approaches: Immunomodulation and trophic support
• Exosome/EV therapy: Cell-free regenerative medicine
• Mitochondrial transplantation: Restoring cellular energy
• Gene therapy: GDNF, CDNF, and related neurotrophic approaches
• Clinical trial landscape: Current status and future opportunities

1. Induced Pluripotent Stem Cell (iPSC) Therapy

1.1 Rationale for iPSC in CBS/PSP

iPSC technology offers unique advantages for 4R-tauopathies:

• Patient-specific modeling: Disease-specific mechanisms can be studied in patient-derived neurons
• Autologous potential: Patient-derived cells may reduce immune rejection
• Genetic correction: CRISPR can correct pathogenic variants before transplantation (e.g., [MAPT](/genes/mapt), [GBA](/genes/gba))
• 4R-tau modeling: Patient iPSCs can be differentiated into neurons expressing 4R-tau isoforms specific to PSP/CBS

1.2 Clinical Status in Parkinson's Disease

Foundational trials in Parkinson's disease establish the template for CBS/PSP applications:

1.3 Adaptation for CBS/PSP

While Parkinson's disease trials focus on dopaminergic neurons, CBS/PSP require additional considerations:

Target Cell Types:

• Dopaminergic neurons for parkinsonian features
• Cholinergic neurons for cognitive/basal forebrain involvement
• GABAergic neurons for cortical inhibition
• Mixed neuronal populations for broader circuit restoration

• [Putamen](/brain-regions/putamen) for motor symptoms
• [Substantia nigra](/brain-regions/substantia-nigra) for native circuit integration
• [Nucleus basalis of Meynert](/brain-regions/nucleus-basalis) for cognitive symptoms
• Multiple regions for distributed pathology

1.4 Patient-Specific iPSC Banking

For patients with resources to pursue personalized approaches:

Cost estimate: $150,000-300,000 for full autologous program

2. Embryonic Stem Cell (ESC) Therapy

2.1 Clinical-Stage ESC Programs

ESC-derived dopaminergic neurons represent the most advanced cell therapy platform:

Bemdaneprocel (BRT-LEW):

• Source: Clinically compliant hESC line
• Product: DA progenitors (post-mitotic)
• Delivery: Stereotactic injection to putamen
• Status: Phase III registrational trial for PD
• Manufacturer: BlueRock Therapeutics (Bayer/BMS)

• Source: Clinically validated hESC line
• Product: Mature dopaminergic neurons
• Delivery: Putaminal transplantation
• Status: Phase I/II in Europe
• Consortium: Lund University, Cambridge University

2.2 Advantages Over iPSC

• Standardized manufacturing: Single-cell line → consistent product
• Scalability: Easier large-scale production
• Regulatory pathway: Established cell line with known characteristics
• Cost: Lower per-dose cost than autologous iPSC

2.3 Considerations for CBS/PSP

ESC programs may expand to atypical parkinsonism after PD registration:

Expected timeline:

• 2026-2027: PD Phase III completion
• 2027-2028: FDA/EMA review and potential approval
• 2028+: Expansion to PSP/CBS trials

• Age <70 (younger patients more likely to benefit)
• Relatively preserved baseline function
• Absence of significant medical comorbidities
• Willingness to undergo immunosuppression

3. Mesenchymal Stem Cell (MSC) Therapy

3.1 Mechanism of Action

MSCs exert therapeutic effects primarily through paracrine mechanisms rather than cell replacement:

3.2 Clinical Evidence in Neurodegeneration

Multiple trials establish safety and preliminary efficacy:

Parkinson's Disease:

• IV MSC: Generally safe, some motor improvement signals
• Intrathecal MSC: Shows promise for neuroinflammation modulation

• Multiple Phase I/II trials establish safety
• Variable efficacy signals depending on delivery route

• Small trials suggest safety
• Autonomic function improvement in some patients

3.3 Application to CBS/PSP

For CBS/PSP patients considering MSC therapy:

Delivery routes: Dosing considerations:

• 1-2 × 10⁶ cells/kg typical dose
• 2-3 infusions spaced 1-2 months apart
• Monitoring: MRI, immunological markers, clinical assessment

• Active trials in PD and ALS establish safety
• Specific CBS/PSP trials expected to emerge 2026-2027

3.4 MSC vs. Neuronal Cell Therapy

4. Exosome/Extracellular Vesicle Therapy

4.1 Rationale

Exosomes (30-150 nm) represent a cell-free approach to regenerative medicine:

• Natural delivery vehicles: Carry parent-cell-derived proteins, RNAs
• BBB penetration: Can cross blood-brain barrier via receptor-mediated transcytosis
• Cargo flexibility: Can be loaded with therapeutic siRNA, ASOs, small molecules
• Safety profile: Lack nuclear DNA, lower oncogenic risk than cells
• Off-the-shelf potential: Scalable manufacturing from cell lines

4.2 Therapeutic Cargo Options

4.3 Stem Cell-Derived EVs

MSCs and neural stem cells secrete therapeutically active exosomes:

MSC-derived EVs:

• Carry immunomodulatory cargo
• Reduce microglial activation in preclinical models
• Safety established in wound healing trials (NCT02565264)

• Disease-specific therapeutic targets
• Patient-derived iPSC neurons for personalized EV production

4.4 Clinical Status

Completed trials:

• Stem cell-derived EVs for wound healing (NCT02565264)
• Cancer immunotherapy (NCT03436356)

• No completed trials in neurodegeneration yet
• Multiple programs in preclinical development

• 2026-2027: First-in-human trials likely in PD
• 2028+: Expansion to tauopathies

5. Mitochondrial Transplantation

5.1 Rationale

Mitochondrial dysfunction is central to CBS/PSP pathology:

• Complex I deficiency: Early finding in substantia nigra
• mtDNA mutations: Accumulate with age, accelerate neurodegeneration
• Mitophagy impairment: Damaged mitochondria accumulate
• Energy crisis: Reduced ATP compromises neuronal function

5.2 Preclinical Evidence

Animal models:

• Mitochondrial transfer improves motor function in PD models
• Astrocyte-to-neuron mitochondrial transfer documented
• Intracerebral delivery shows neuronal uptake

• Direct mitochondrial incorporation
• Tunneling nanotube transfer
• Extracellular vesicle-mediated delivery

5.3 Clinical Trial Status

NCT04998357 (University of Washington):

• First human brain mitochondrial transplantation
• Phase I, safety focus
• Safe in initial cohort

5.4 Application to CBS/PSP

Suitability factors:

• Strong mitochondrial pathology in PSP
• Target: substantia nigra, basal ganglia
• May combine with other cell therapies

6. Neurotrophic Factor Gene Therapy

6.1 GDNF Gene Therapy

[GDNF](/proteins/gdnf-protein) (Glial Cell Line-Derived Neurotrophic Factor) is the most extensively studied neurotrophic factor for parkinsonism.

Mechanism:

• Potent dopaminergic neuron survival factor
• Supports axonal sprouting
• Protects substantia nigra neurons

Challenges:

• AAV2 limited to neurons expressing appropriate receptors
• Distribution across putamen requires multiple injection tracks
• GDNF not secreted efficiently from transduced cells
• Clinical trials in PD showed mixed results

• AAV5 or AAV9 for broader transduction
• AAV-GDNF with optimized secretion
• Combinations with cell therapy

6.2 CDNF Gene Therapy

[CDNF](/proteins/cdnf-protein) (Cerebral Dopamine Neurotrophic Factor) offers advantages over GDNF:

Mechanism:

• ER stress reduction
• Unfolded protein response modulation
• Anti-apoptotic effects
• Both dopaminergic and non-dopaminergic protection

• Phase I/II trial (NCT04174190): First-in-human AAV-CDNF
• Delivery: Intracerebral to putamen
• Sponsor: Herantis Pharma
• Status: Ongoing, safety established

• Secreted protein (better diffusion)
• ER stress protection relevant to tauopathies
• May benefit non-dopaminergic circuits

6.3 NTRK2 Gene Therapy

[TrkB](/proteins/trkb-protein) (NTRK2) activation supports multiple neuronal populations:

• BDNF signaling: Synaptic plasticity, cognitive function
• GABAergic neurons: Cortical inhibition
• Cholinergic neurons: Basal forebrain function

6.4 Gene Therapy for CBS/PSP

7. Combination Cell Therapy Approaches

7.1 Cell Therapy + Immunomodulation

Combining neuronal cell replacement with anti-inflammatory approaches:

Rationale:

• Transplanted cells face hostile neuroinflammatory environment
• Reducing microglia activation improves graft survival
• TREM2 modulators may enhance phagocytosis of pathological tau

• MSC co-transplantation: MSC + neuronal progenitors
• CSF1R inhibitor preconditioning
• Anti-inflammatory cytokine delivery

7.2 Cell Therapy + Neurotrophic Support

Enhancing graft survival and integration:

GDNF-secreting cells:

• Engineered cells co-expressing GDNF
• Sustained neurotrophic support at transplant site

• Exercise + cell therapy: synergistic BDNF elevation
• CoQ10 + cell therapy: enhanced mitochondrial function

7.3 Sequential Therapy Protocols

Multi-phase treatment strategies:

Phase 1: Immunomodulation

• MSC or anti-inflammatory treatment
• Reduce hostile microenvironment

• iPSC or ESC-derived neurons
• Establish new circuits

• Exercise, BDNF elevation
• Neurotrophic factor support

• Repeat MSC treatments
• Monitor and support long-term function

8. Clinical Trial Opportunities

8.1 Active Trials to Monitor

8.2 How to Access These Therapies

For patients with resources:

Key institutions:

• Kyoto University (Japan): iPSC program
• McGill University: NTRK2 trials
• Lund University: STEM-PD
• University of Washington: Mitochondrial transplantation

8.3 Future CBS/PSP-Specific Trials

Expected based on PD timeline:

2027-2028:

• First ESC or iPSC trials in PSP likely
• CDNF expansion to PSP
• MSC trials in CBS/PSP

• Registrational trials if early signals positive
• Combination therapy approaches
• Personalized iPSC programs

9. Practical Considerations

9.1 Patient Selection Criteria

Factors predicting better outcomes:

9.2 Risk-Benefit Assessment

Potential benefits:

• Motor function improvement
• Disease modification (if cell therapy effective)
• Reduced medication needs
• Improved quality of life

• Surgical complications (hemorrhage, infection)
• Immunosuppression-related complications
• Graft failure or rejection
• Tumor formation (theoretical, very low with current protocols)
• Dyskinesias (particularly with cell therapy)

9.3 Cost Considerations

10. Integration with Treatment Plan

10.1 Positioning Cell Therapy

Cell and regenerative therapies should be positioned within the broader treatment framework:

Immediate term (now):

• Exercise, existing medications, clinical trial participation
• Standard disease management

• Monitor PD cell therapy trials
• Consider MSC therapy if available
• Prepare for eventual CBS/PSP trials

• Access to first-generation cell therapies
• Potential combination approaches
• Personalized iPSC options for those with resources

10.2 Connection to Other Sections

• [Section 215: Combination Therapy Synergies](/therapeutics/section-215-combination-therapy-synergies-cbs-psp) — combining cell therapy with small molecules
• [Stem Cell Therapy for Atypical Parkinsonism](/therapeutics/stem-cell-therapy-parkinsonism) — foundational content
• [Mitochondrial Transplantation](/therapeutics/mitochondrial-transplantation-neurodegeneration) — detailed mechanisms
• [Gene Therapy Overview](/therapeutics/gene-therapy) — complementary approach
• [Custom R&D](/therapeutics/cbs-psp-custom-rd) — N-of-1 trial options

11. Conclusion

Advanced cell therapy and regenerative medicine represent the frontier of CBS/PSP treatment. While Parkinson's disease establishes the clinical foundation, translation to 4R-tauopathies will follow. Key considerations:

Near-term opportunities:

• MSC therapy for immunomodulation
• Monitor AAV-CDNF expansion
• Mitochondrial transplantation trials

• ESC/iPSC trials likely in PSP by 2027-2028
• Personalized iPSC for select patients
• Combination approaches emerging

• Monitor trial databases (ClinicalTrials.gov)
• Establish care at academic centers
• Consider cell banking for future use
• Maintain overall health to remain trial-eligible

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
• [Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PIEZO1 and KCNK2
• [Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: DGAT1 and SOAT1
• [TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TREM2
• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
• [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
• [TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: TREM2

• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) &#x1f504;
• [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;